JP2006508980A - Ｇｓｔ活性化された抗癌化合物と他の抗癌治療との併用癌治療 - Google Patents

Ｇｓｔ活性化された抗癌化合物と他の抗癌治療との併用癌治療 Download PDF

Info

Publication number
JP2006508980A
JP2006508980A JP2004553614A JP2004553614A JP2006508980A JP 2006508980 A JP2006508980 A JP 2006508980A JP 2004553614 A JP2004553614 A JP 2004553614A JP 2004553614 A JP2004553614 A JP 2004553614A JP 2006508980 A JP2006508980 A JP 2006508980A
Authority
JP
Japan
Prior art keywords
cancer
gst
anticancer
activated
tlk286
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004553614A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006508980A5 (enExample
Inventor
シュ・フア
ゲイル・エル・ブラウン
スティーブン・アール・ショー
ジェイムズ・ジー・ケック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Terrapin Technologies Inc
Original Assignee
Terrapin Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Terrapin Technologies Inc filed Critical Terrapin Technologies Inc
Publication of JP2006508980A publication Critical patent/JP2006508980A/ja
Publication of JP2006508980A5 publication Critical patent/JP2006508980A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2004553614A 2002-11-15 2003-11-14 Ｇｓｔ活性化された抗癌化合物と他の抗癌治療との併用癌治療 Pending JP2006508980A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42698302P 2002-11-15 2002-11-15
PCT/US2003/036209 WO2004045593A2 (en) 2002-11-15 2003-11-14 Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010162154A Division JP2010265305A (ja) 2002-11-15 2010-07-16 Ｇｓｔ活性化された抗癌化合物と他の抗癌治療との併用癌治療

Publications (2)

Publication Number Publication Date
JP2006508980A true JP2006508980A (ja) 2006-03-16
JP2006508980A5 JP2006508980A5 (enExample) 2006-12-28

Family

ID=32326463

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004553614A Pending JP2006508980A (ja) 2002-11-15 2003-11-14 Ｇｓｔ活性化された抗癌化合物と他の抗癌治療との併用癌治療
JP2010162154A Pending JP2010265305A (ja) 2002-11-15 2010-07-16 Ｇｓｔ活性化された抗癌化合物と他の抗癌治療との併用癌治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010162154A Pending JP2010265305A (ja) 2002-11-15 2010-07-16 Ｇｓｔ活性化された抗癌化合物と他の抗癌治療との併用癌治療

Country Status (12)

Country Link
US (2) US20040138140A1 (enExample)
EP (1) EP1562564A2 (enExample)
JP (2) JP2006508980A (enExample)
KR (1) KR20050075018A (enExample)
CN (2) CN101590229B (enExample)
AR (1) AR042051A1 (enExample)
AU (2) AU2003290805A1 (enExample)
BR (1) BR0316364A (enExample)
CA (1) CA2505377A1 (enExample)
MX (1) MXPA05005200A (enExample)
TW (1) TWI323662B (enExample)
WO (1) WO2004045593A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007538105A (ja) * 2004-05-20 2007-12-27 テリック，インコーポレイテッド Ｇｓｔ活性化抗癌化合物による治療による別の抗癌療法の増感および／または別の抗癌療法の副作用の改善
WO2010086964A1 (ja) * 2009-01-28 2010-08-05 株式会社 静岡カフェイン工業所 がん治療のための併用療法
JP2014221843A (ja) * 2007-09-10 2014-11-27 ボストン バイオメディカル， インコーポレイテッド 癌治療のための新規の組成物および方法

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0011903D0 (en) * 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
JP5371426B2 (ja) * 2004-07-09 2013-12-18 プロルックス ファーマシューティカルズ コープ． ワートマニン類似体及び化学療法薬と組み合わせた同一物を使用する方法
WO2006074249A1 (en) * 2005-01-06 2006-07-13 Telik, Inc. Tripeptide and tetrapeptide thioethers
US8168661B2 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8178564B2 (en) * 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US20110033528A1 (en) * 2009-08-05 2011-02-10 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
TW200920347A (en) * 2007-07-16 2009-05-16 Poniard Pharmaceuticals Inc Oral formulations for picoplatin
JP2011511072A (ja) * 2008-02-08 2011-04-07 ポニアード ファーマシューティカルズ， インコーポレイテッド 結腸直腸癌を治療するためのピコプラチンおよびベバシツマブの使用
AU2009228303B2 (en) * 2008-03-25 2015-08-13 Paloma Pharmaceuticals, Inc. Methods of treating fibrotic disorders
EP2425830A1 (en) * 2010-09-03 2012-03-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synergistic drug combination for the treatment of cancer
US20140296178A1 (en) * 2010-12-01 2014-10-02 Niiki Pharma Acquisition Corp. 2 Combination Therapy with a Gallium Complex
WO2012112791A1 (en) * 2011-02-16 2012-08-23 Paloma Pharmaceuticals, Inc. Radiation countermeasure agents
US20120251496A1 (en) * 2011-03-31 2012-10-04 Telik, Inc. Ezatiostat for treating multiple myeloma
WO2014169078A2 (en) 2013-04-09 2014-10-16 Boston Biomedical, Inc. Methods for treating cancer
US20170080093A1 (en) * 2013-10-22 2017-03-23 Tyme, Inc. Tyrosine Derivatives And Compositions Comprising Them
BR112017000800A8 (pt) * 2014-07-17 2023-04-25 Biocurity Holdings Inc Tratamento do câncer com uma combinação de radiação, nanoparticulas de óxido de cério, e um agente quimioterápico
US11389536B2 (en) 2015-07-17 2022-07-19 BioCurity Pharmaceuticals Inc. Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent
CA3045306A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
EA201991305A1 (ru) * 2016-11-30 2019-10-31 Производные тирозина и композиции, включающие их
JP2020520923A (ja) 2017-05-17 2020-07-16 ボストン バイオメディカル， インコーポレイテッド がんを処置するための方法
KR102861344B1 (ko) * 2020-09-28 2025-09-17 미츠비시 파워 가부시키가이샤 증기 터빈

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09506074A (ja) * 1993-10-01 1997-06-17 テラピン テクノロジーズ，インコーポレイテッド グルタチオン‐ｓ‐トランスフェラーゼ活性化化合物
WO2000066093A2 (en) * 1999-04-29 2000-11-09 Pharmacia & Upjohn S.P.A. Combined preparations comprising morpholine anthracyclines and anticancer agent
WO2001060365A1 (en) * 2000-02-17 2001-08-23 Merck & Co., Inc. Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug
WO2002056692A1 (en) * 2000-12-22 2002-07-25 Bristol-Myers Squibb Company Methods for modulating tumor growth and metastasis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5599903A (en) * 1992-04-03 1997-02-04 Terrapin Technologies, Inc. Glutathione analogs and paralog panels comprising glutathione mimics
US5545621A (en) * 1991-04-29 1996-08-13 Terrapin Technologies, Inc. Glutathione S-transferase-activated compounds
US5955432A (en) * 1992-04-03 1999-09-21 Terrapin Technologies, Inc. Metabolic effects of certain glutathione analogs
US5767147A (en) * 1995-04-21 1998-06-16 The Regents Of The University Of California Inhibition of glutathione transferase by haloenol lactones
ATE280582T1 (de) * 1995-06-07 2004-11-15 Telik Inc Stoffwechseleffekt von bestimmten glutation analogen
US5880097A (en) * 1996-01-04 1999-03-09 Terrapin Techologies, Inc. Tethered prodrugs
US20030073837A1 (en) * 1998-12-31 2003-04-17 Langecker Peter J. 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy
US6281223B1 (en) * 1999-04-13 2001-08-28 Supergen, Inc. Radioenhanced camptothecin derivative cancer treatments
TW200538149A (en) * 2004-05-20 2005-12-01 Telik Inc Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09506074A (ja) * 1993-10-01 1997-06-17 テラピン テクノロジーズ，インコーポレイテッド グルタチオン‐ｓ‐トランスフェラーゼ活性化化合物
WO2000066093A2 (en) * 1999-04-29 2000-11-09 Pharmacia & Upjohn S.P.A. Combined preparations comprising morpholine anthracyclines and anticancer agent
WO2001060365A1 (en) * 2000-02-17 2001-08-23 Merck & Co., Inc. Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug
WO2002056692A1 (en) * 2000-12-22 2002-07-25 Bristol-Myers Squibb Company Methods for modulating tumor growth and metastasis

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN5005011677, "Ｔｗｏ ｓｅｃｏｎｄａｒｙ ｏｆｆｅｒｉｎｇｓ ｈｏｐｅｆｕｌ", ＳＣＲＩＰ, 20021016, Ｎ２７９０, Ｐ１２ *
JPN6010000181, ＳＡＴＹＡＭ， Ａ．， ｅｔ ａｌ．, "Ｄｅｓｉｇｎ， Ｓｙｎｔｈｅｓｉｓ， ａｎｄ ｅｖａｌｕａｔｉｏｎ ｏｆ Ｌａｔｅｎｔ Ａｌｋｙｌａｔｉｎｇ Ａｇｅｎｔｓ Ａｃｔｉｖａｔｅｄ ｂｙ Ｇｌｕｔａｔｈｉｏｎｅ Ｓ−Ｔｒａｎｓｆｅｒａｓｅ", Ｊｏｕｒｎａｌ ｏｆ Ｍｅｄｉｃｉｎａｌ Ｃｈｅｍｉｓｔｒｙ, 19960412, Ｖｏｌ．３９， Ｎｏ．８, ｐ．１７３６−１７４７ *
JPN6010000186, ＲＯＳＡＲＩＯ， Ｌ．Ａ．， ｅｔ ａｌ．, "Ｃｅｌｌｕｌａｒ Ｒｅｓｐｏｎｓｅ ｔｏ ａ Ｇｌｕｔａｔｈｉｏｎｅ Ｓ−Ｔｒａｎｓｆｅｒａｓｅ Ｐ１−１ Ａｃｔｉｖａｔｅｄ Ｐｒｏｄｒｕｇ", Ｍｏｌｅｃｕｌａｒ Ｐｈａｒｍａｃｏｌｏｇｙ, 200007, Ｖｏｌ．５８， Ｎｏ．１, ｐ．１６７−１７４ *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007538105A (ja) * 2004-05-20 2007-12-27 テリック，インコーポレイテッド Ｇｓｔ活性化抗癌化合物による治療による別の抗癌療法の増感および／または別の抗癌療法の副作用の改善
JP2014221843A (ja) * 2007-09-10 2014-11-27 ボストン バイオメディカル， インコーポレイテッド 癌治療のための新規の組成物および方法
JP2016065101A (ja) * 2007-09-10 2016-04-28 ボストン バイオメディカル， インコーポレイテッド 癌治療のための新規の組成物および方法
US10377731B2 (en) 2007-09-10 2019-08-13 Boston Biomedical, Inc. Compositions and methods for cancer treatment
US10851075B2 (en) 2007-09-10 2020-12-01 Sumitomo Dainippon Pharma Oncology, Inc. Stat3 pathway inhibitors and cancer stem cell inhibitors
WO2010086964A1 (ja) * 2009-01-28 2010-08-05 株式会社 静岡カフェイン工業所 がん治療のための併用療法

Also Published As

Publication number Publication date
TW200412933A (en) 2004-08-01
CN101590229B (zh) 2012-12-05
AU2010200483A1 (en) 2010-03-04
CN101590229A (zh) 2009-12-02
AR042051A1 (es) 2005-06-08
CN100508961C (zh) 2009-07-08
CA2505377A1 (en) 2004-06-03
US20040138140A1 (en) 2004-07-15
MXPA05005200A (es) 2005-08-18
TWI323662B (en) 2010-04-21
AU2003290805A1 (en) 2004-06-15
BR0316364A (pt) 2005-10-04
KR20050075018A (ko) 2005-07-19
EP1562564A2 (en) 2005-08-17
WO2004045593A3 (en) 2004-08-12
CN1711076A (zh) 2005-12-21
WO2004045593A2 (en) 2004-06-03
US20080159980A1 (en) 2008-07-03
JP2010265305A (ja) 2010-11-25

Similar Documents

Publication Publication Date Title
JP2010265305A (ja) Ｇｓｔ活性化された抗癌化合物と他の抗癌治療との併用癌治療
US8207121B2 (en) Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound
JP2006508980A5 (enExample)
JP4991107B2 (ja) コンブレタスタチンおよび抗癌剤からなる組成物
US6699844B2 (en) Methods for treating cellular proliferative disorders
US20200123153A1 (en) Combinations for immune-modulation in cancer treatment
JP2016515625A (ja) 増殖性疾患を治療するための併用療法
US20210023099A1 (en) Combination therapy with a bet inhibitor and a proteasome inhibitor
Schilder et al. New therapies for ovarian cancer
US20200237779A1 (en) Combination therapy with a bet inhibitor and a bcl-2 inhibitor
Natsume et al. Combination effect of TZT-1027 (Soblidotin) with other anticancer drugs

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061113

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100119

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100416

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100423

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100512

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100519

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100621

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100716

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20100716

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100817